My research focuses on improving clinical outcome measures and intervention outcomes for individuals with Down syndrome, neurodevelopmental disorders, and other special healthcare needs. I conduct research in real-world, clinical settings using multiple different tools, including caregiver-report, behavioral assessments, and electroencephalography (EEG) to study the development of and interventions for challenging behaviors. I am currently a KL2 INCLUDE Scholar conducting research on cognitive abilities and challenging behaviors in youth with Down syndrome.
Caitlin Courshon, PhD (she/her), is an attending psychologist for the Behavior and Attention Management (BAM) Program within Outpatient Psychiatry at Seattle Children’s Hospital and an Acting Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington. Dr. Courshon has clinical expertise in the treatment, consultation, and assessment of children with disruptive behaviors and their families, including, but not limited to, neurodevelopmental disorders such as attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, and disruptive behavior disorders. Her clinical work integrates evidence-based treatments, including parent behavior management training (PBMT), cognitive-behavioral therapy (CBT), and dialectical behavior therapy (DBT).
Dr. Courshon’s current academic interests focus on researching clinical outcomes of PBMT programs and contributing to ongoing program development to expand services for caregivers navigating challenges related to home-school communication and disruptive behaviors in school settings. She is deeply committed to helping children improve their behaviors, empowering caregivers and educators to enhance their self-efficacy in supporting children with disruptive behaviors, and fostering healthy, safe, and inclusive environments across home, school, and community settings.
I am a child and adolescent psychiatrist committed to improving outcomes for young people who face complex difficulties and systemic barriers. As a clinician, I aim to establish meaningful therapeutic relationships with young people and those supporting them, while also working to advocate for public policy and health systems that improve access to quality mental healthcare.
My main role includes providing inpatient care to older adolescents at the Child Study and Treatment Center through the Behavioral Health Administration, Washington State Department of Social and Health Services, and acting as training lead for psychiatry at this site. My clinical interests include the transition from adolescence to adulthood, the emergence of mood disorder and psychosis, early intervention for personality disorder, and developmental disabilities. I have academic interest in medical education, health service development, and the social determinants of mental health.
My work focuses on the development, dissemination, and implementation of tools for the assessment and treatment of autism spectrum disorder. I am also interested in transdiagnostic interventions for autism spectrum disorder to increase efficacy for individuals and families, as well as access to care. My clinical pursuits include conducting diagnostic evaluations for autism for youth of all ages, as well as running groups and classes for autistic individuals and their families.
I am a consult psychiatrist and clinical instructor at the Fred Hutch Cancer Center. I work with people undergoing active cancer care. I previously practiced in the VA outpatient mental health clinic with veterans with mood disorders, anxiety, post-traumatic stress disorder, and chronic and serious mental illness. I recently worked as a consult psychiatrist with the Swedish Primary Care Clinics, address a wide variety of concerns in a collaborative behavioral health care setting. I enjoy being a part of medical education, both learning and teaching. However, patient care always comes first.
Sheena Friesen, PhD (she/her), is the attending psychologist for the Child Program on the inpatient Psychiatry and Behavioral Medicine Unit at Seattle Children’s Hospital and Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington. She has clinical expertise in disruptive behavior disorders, comprehensive assessment, Dialectical Behavior Therapy, Exposure Therapies, Parent Training, and Trauma-Focused Cognitive Behavioral Therapy.
Dr. Friesen’s research interests broadly focus on advancing knowledge of least restrictive interventions in acute and complex care contexts, trauma-informed care, and interventions designed to address children’s disruptive behavior problems. She has collaborated on and co-led efforts to design and implement a multi-tiered, Modified Positive Behavioral Interventions and Supports (M-PBIS) model of care aimed at increasing positive behavior interventions, reducing restraint and PRN use, and ameliorating racial gaps in care delivery.
Dr. Friesen received her Ph.D. in School Psychology from the University of Washington in Seattle, WA. She completed her pre-doctoral internship training at Johns Hopkins School of Medicine and Kennedy Krieger Institute and went on to complete her postdoctoral fellowship in acute care and clinical psychology at Seattle Children’s Hospital.
My clinical and research interests center around behavioral and psychological symptoms that present in neurodegenerative diseases, especially dementias. Though dementia is well-known to affect one’s memory and cognition, over 90% of people with dementia develop new neuropsychiatric symptoms – including apathy, dysphoria. anxiety, aggression, agitation, disinhibition, hallucinations, and delusions. Despite the ubiquity of these symptoms, very little is known about how they develop in dementia. My research interests are in understanding more about the molecular and cellular mechanisms of neuropsychiatric symptoms in dementia beyond the well-studied changes associated with cognitive deficits.
Along with my research mentor Martin Darvas PhD (Department of Laboratory Medicine and Pathology), we employ numerous approaches to better understand these neuropsychiatric symptoms, including techniques involving transcriptomic analyses of human and mouse post-mortem tissue, development and implementation of biomarkers derived from human and animal model fluids (plasma, serum, cerebrospinal fluid), virally-mediated gene manipulations, animal modeling of cognitive and neuropsychiatric phenotypes, and basic cellular and molecular biology techniques.
